Disclosure Of First-Time Adoption [Text Block]

Innate Pharma - Filing #5981200

Concept	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	—	336 893 EUR	—	—	—	390 979 EUR	—	4 192 EUR	1 018 EUR	—	1 045 EUR	—	8 834 EUR	27,000 EUR	—	49 471 EUR	—	—	51 901 EUR	329 323 EUR	7 570 EUR	—	1 009 EUR	—	—	—	384 255 EUR	—	4 044 EUR	514,000 EUR	—	495,000 EUR	54 151 EUR	272 213 EUR	58 103 EUR	615,000 EUR	819,000 EUR	379 637 EUR	4 011 EUR	204,000 EUR
Comprehensive income	49 471 EUR	—	— EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	—	49 939 EUR	—	—	468,000 EUR	—	6 900 EUR	7 570 EUR	—	—	—	994,000 EUR	—	— EUR	— EUR	— EUR	—	— EUR	—	—	324,000 EUR	—	—	—	—	—	—	—	—	—
Profit (loss)	49 471 EUR	—	— EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	—	49 471 EUR	—	—	— EUR	—	7 570 EUR	7 570 EUR	—	—	—	— EUR	—	— EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	—	—	—	—	—	—	—	—	—